Novartis and Pear Therapeutics to create new digital therapies

Novartis has announced a new collaboration with Pear Therapeutics that will focus on the development of new digital therapies for a number of conditions.

The companies will work to produce software applications to treat schizophrenia and multiple sclerosis, and improve clinical outcomes for patients. The work will leverage Novartis' expertise in biomedical research and clinical development, as well as leading experience in designing and implementing digital therapeutics.

Pear's existing solutions are designed to deliver clinically-proven techniques, such as cognitive behavioural therapy, through mobile and desktop applications, complementing drug therapies for these conditions.

This collaboration will specifically focus on advancing clinical development of the Thrive digital therapy platform for patients with schizophrenia, which has demonstrated strong usability, retention and preliminary efficacy in early clinical studies.

Dr Jay Bradner, president of the Novartis Institutes for Biomedical Research, said: "With widespread adoption of digital devices, prescription digital therapeutics could potentially play an important role in future treatment models for a range of diseases with high unmet medical need."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.